Last reviewed · How we verify
Satraplatin in combination with Paclitaxel — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Satraplatin in combination with Paclitaxel (Satraplatin in combination with Paclitaxel) — Agennix.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Satraplatin in combination with Paclitaxel TARGET | Satraplatin in combination with Paclitaxel | Agennix | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Satraplatin in combination with Paclitaxel CI watch — RSS
- Satraplatin in combination with Paclitaxel CI watch — Atom
- Satraplatin in combination with Paclitaxel CI watch — JSON
- Satraplatin in combination with Paclitaxel alone — RSS
Cite this brief
Drug Landscape (2026). Satraplatin in combination with Paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/satraplatin-in-combination-with-paclitaxel. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab